Weight loss drug trends for employers to know in 2024 - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Health/Employee Benefits News
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Health/Employee Benefits News
Health/Employee Benefits News RSS Get our newsletter
Order Prints
December 28, 2023 Health/Employee Benefits News
Share
Share
Post
Email

Weight loss drug trends for employers to know in 2024

By Nathan Cassin

As we turn the page toward 2024, employers and employees are thinking about their health plans and needs. Over recent years, we’ve seen new pharmacy and drug trends taking over the industry. As pharmacy director for Holmes Murphy, I’m closely following new pharmacy developments and what employers should be aware of heading into next year, including the increasing popularity of weight loss medications. How well do these medications work and should employers offer plans that cover these drugs?

Nathan Cassin

Let’s preface by understanding the origination of when these weight loss medications came around. In 2005, a class of medications hit the market for treatment of type 2 diabetes (T2 diabetes), called glucagon-like peptide 1 (GLP-1) receptor agonists. These drugs mimic the action of a hormone called GLP-1, which works by reducing appetite, slowing the release of food from the stomach, and increasing feelings of fullness after eating. Ozempic (semaglutide) hit the marketplace in 2017 for treatment of T2 diabetes, while Wegovy (semaglutide) was approved in 2021 for chronic weight management. Zepbound (terzepitide) received approval as an anti-obesity medication (AOM) on Nov. 8.

Studies found that people who were using semaglutide and making lifestyle changes lost about 33.7 pounds (15.3 kilograms) versus 5.7 pounds (2.6 kilograms) among those who didn't use the drug. Most weight loss drugs are intended to be used along with diet and exercise. They’re intended for use in adults with a body mass index greater than 30 or a BMI of 27 or higher when a patient presents one or more obesity related comorbidities, which is the Center for Disease Control’s obesity standard. People who take these medications without behavior modification will use them for the long haul as stopping will make their appetite return.

Most people can tolerate GLP-1s well. The most common side effects (nausea, vomiting and diarrhea) are usually mild and occur in the first few weeks of treatment, and then reduce over time. Some severe reactions such as gut paralysis have been noted along with correlation investigations in Europe for upticks in suicidal thoughts.

Employers must be aware of and understand the trends that may come about soon. Coverage of weight loss medications are likely to expand once market competition increases and adherence challenges are addressed. It’s anticipated that oral treatments and lower out-of-pocket costs should increase adherence. Plan sponsors that cover anti-obesity medications must be aware of success bias, as patients lower their BMIs through using medications of which prior authorization criteria is not weight-based for continued treatment.

It's also important to know the cost range for these popular medications. The list price for Zepbound is $1,059, which is about 20% lower than the current list price of Wegovy. Uninsured patients may be able to obtain a 50% discount on list prices. Recent Morgan Stanley research predicts that competition in this class will reduce monthly drug costs from $1,300 per month to $450 by 2025 and $350 by 2026.

Employers should consider several options regarding employee health plans and weight loss medications. Some considerations include moving from a traditional pharmacy benefits manager to an acquisition cost-plus PBM, determining prior authorization and utilization management criteria that serve your needs, and using coverage as an employee retention and talent attraction tool.\

I believe this form of pharmaceutical support should be offered in combination with lifestyle and behavior support. The medication alone will not be a long-term cure; it must be coupled with behavioral change. For employers, behavior support can be provided through a proven weight-management vendor, connection with a registered dietitian, or research.

There are various reasons for employers to offer weight-loss medications. Understanding the details, trends, and considerations will be great factors for the decision.

 

Nathan Cassin serves as pharmacy director at Holmes Murphy & Associates. Contact him at nathan.cassin@innfeedback.com.

 

© Entire contents copyright 2023 by InsuranceNewsNet.com Inc. All rights reserved. No part of this article may be reprinted without the expressed written consent from InsuranceNewsNet.com.

Nathan Cassin

Older

NAIC ‘greatly disappointed’ in DOL diss of state annuity sales rules

Newer

Life sales review: a 2023 sales dip should reverse in 2024, LIMRA says

Advisor News

  • Survey: Most Americans still feel prosperous despite economic worries
  • SEC settlement would require Tai Lopez, two others, to pay $6.8 million
  • The Gen Z money paradox
  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
More Advisor News

Annuity News

  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • Boomers want retirement protection, but their actions don’t match their mindset
  • NAIC task force to address LTC riders
More Annuity News

Life Insurance News

  • AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
  • AM Best Takes Various Credit Rating Actions on Certain Subsidiaries of Auto-Owners Insurance Group
  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • AM Best Downgrades Credit Ratings of CICA Life Insurance Company of America
  • AM Best Upgrades Credit Ratings of CTBC Insurance Company Ltd
More Life Insurance News

Property and Casualty News

  • AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
  • AM Best Affirms Credit Ratings of NongHyup Property and Casualty Insurance Company Limited
  • AM Best Affirms Credit Ratings of Delphi Financial Group, Inc. and Its Subsidiaries; Upgrades Issuer Credit Rating of Standard Security Life Insurance Company of New York
  • State Farm, Wests, State settle lawsuits
  • November Issue of Best’s Review Ranks US Life Reinsurers and More
More Property and Casualty News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.